Live Feeds
● TRACKER Updated 16d ago · 6 sources tracked

People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds

A clinical trial found that people with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, specifically direct oral anticoagulants (DOACs). The trial, SINGLE-AF, showed that DOACs cut clinical events in these patients. This finding supports the use of DOACs in this patient population.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants.
  • ✓ Direct oral anticoagulants (DOACs) cut clinical events in atrial fibrillation patients at intermediate stroke risk.
🛡️ Source Corroboration: 6 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The SINGLE-AF trial provided evidence that DOACs benefit atrial fibrillation patients at intermediate stroke risk, which may lead to changes in treatment guidelines.

Live updates

  1. Oral Anticoagulants Benefit Atrial Fibrillation Patients at Intermediate Stroke Risk

    A clinical trial found that people with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, specifically direct oral anticoagulants (DOACs). The trial, SINGLE-AF, showed that DOACs cut clinical events in these patients. This finding supports the use of DOACs in this patient population.

    Why it matters

    Atrial fibrillation is a common heart condition that increases the risk of stroke. Oral anticoagulants are often prescribed to patients at high risk of stroke, but the benefit for those at intermediate risk was unclear. The SINGLE-AF trial aimed to fill this knowledge gap. The trial's results have implications for the treatment of atrial fibrillation patients.

    What is confirmed

    • People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants.
    • Direct oral anticoagulants (DOACs) cut clinical events in atrial fibrillation patients at intermediate stroke risk.

    What to watch next

    • Guideline updates incorporating SINGLE-AF trial results
    • Further studies on the long-term effects of DOACs in atrial fibrillation patients
    • Regulatory reviews of DOACs for atrial fibrillation treatment
    Sources used for this update (6)
    1. Medical Xpress — People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds
    2. Medscape — SINGLE-AF: DOACs Cut Clinical Events in AF Patients at Intermediate Stroke Risk
    3. News-Medical — New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage
    4. TCTMD.com — DOACs Benefit AF Patients With Intermediate Stroke Risk: SINGLE-AF
    5. HCPLive — ENRICH-AF: Edoxaban Increases Bleeding Without Reducing Stroke
    6. medicalxpress.com — People who could benefit from blood pressure medication may be missing out on treatment
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community